Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
scAAV9.P546.SLC6A1 for SLC6A1 Neurodevelopmental Disorder
NCT07173153Phase 2Enrolling by invitation
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of TSHA-103 in SLC6A1-related neurodevelopmental disorder (SLC6A1-NDD). Started Aug 2025; status: enrolling by invitation.
02
Drugs
TSHA-103
03
Conditions
SLC6A1-related neurodevelopmental disorder (SLC6A1-NDD)
Beyond the preview
Go deeper on NCT07173153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07173153.